key: cord-0904996-lsr2d7rk
authors: Koyasu, Sho; Nakamoto, Yuji
title: (111)In-Pentetreotide Uptake Due to COVID-19 Vaccination
date: 2021-10-06
journal: Clin Nucl Med
DOI: 10.1097/rlu.0000000000003935
sha: 7b30949347bec2f871149a8a871576f6b94b2678
doc_id: 904996
cord_uid: lsr2d7rk

A 72-year-old woman was referred for whole-body (111)In-pentetreotide scintigraphy with SPECT/CT. There was increased uptake of lymphadenopathy in the left axilla and left deltoid muscle. The patient's history revealed that the patient received the first dose of the COVID-19 vaccine 3 days before the (111)In-pentetreotide scintigraphy with SPECT/CT. This case demonstrates that the COVID-19 vaccine can cause (111)In-pentetreotide uptake in the lymph nodes and the deltoid muscle.

A 72-year-old woman was referred to whole-body 111 In-pentetreotide scintigraphy with SPECT/CT, suspecting recurrence of neuroendocrine tumor (NET). She underwent surgery for colon NET and liver metastasis 6 years ago. There were focal uptakes of 111 In-pentetreotide in the lower abdomen and left upper arm on the 24-hour planar image (A, arrow and arrowhead, respectively). On the SPECT/CT, there was increased uptake in the area of lymphadenopathy at the left axilla and the left deltoid muscle (B), as well as the sacrum, which is consistent with bone metastasis of NET (C, arrow). Given that the lymph nodes were not noticeable on the CT, taken 8 days earlier than the 111 In-pentetreotide scintigraphy (not shown), the axillary lymph node enlargement (D) was believed to have occurred during the 8 days. The patient's medical history showed that she received the first dose of the COVID-19 vaccine as an intramuscular injection to the left deltoid muscle, 3 days before the 111 In-pentetreotide scintigraphy with SPECT/CT. With the recent widespread use of COVID-19 vaccination, it is not uncommon to see transient FDG uptake in morphologically normal or mildly enlarged lymph nodes located in the axilla and sometimes on the supraclavicular or the neck after intramuscular vaccination of the ipsilateral deltoid muscle. [1] [2] [3] [4] This case demonstrates 111 In-pentetreotide uptake due to COVID-19 vaccination in a pattern identical to that of FDG PET. Although it has not been reported whether 111 In-pentetreotide accumulates in the muscles or lymphoid tissues after vaccination, lymphatic cells are known to express somatostatin receptors. 5 68 Ga-DOTA TOC/TATE uptake is commonly seen in inflammatory lymph nodes, 6, 7 including lymphadenopathy due to COVID-19 vaccination. [8] [9] [10] As with FDG PET/CT, information about vaccination may help avoid unnecessary testing during somatostatin receptor imaging.

Association of COVID-19 mRNAvaccine with ipsilateral axillary lymph node reactivity on imaging

Imaging of COVID-19 vaccination at FDG PET/CT. Radiology

COVID-19 mRNA vaccination: age and immune status and its association with axillary lymph node PET/CT uptake

COVID-19 vaccinationrelated uptake on FDG PET/CT: an emerging dilemma and suggestions for management

In vitro autoradiographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue

Neuroendocrine tumor imaging with 68 Ga-DOTA-NOC: physiologic and benign variants

The utility of PET/CT with (68)Ga-DOTATOC in sarcoidosis: comparison with (67)Ga-scintigraphy

[(68)Ga]Ga-DOTA-TATE uptake due to COVID-19 vaccination

DOTATATE-avid bilateral axilla and subpectoral lymphadenopathy induced from COVID-19 mRNAvaccination visualized on PET/CT

DOTATATE uptake in an axillary lymph node after COVID-19 vaccination